Bedrocan Finally Declared Bankrupt

Bedrocan, Europe’s pioneering medical cannabis company, was finally declared bankrupt on Wednesday, October 7, 2026, by a Dutch court, less than two weeks after they were placed under a suspension regime provisional payments.

This decision, which affects Bedrocan Nederland B.V. and Bedrocan International B.V., marks a turning point for the company, which had been supplying the Dutch government with medical cannabis for more than twenty years.

Beyond its disappearance from the domestic market, it is now the continuity of treatment which is causing concern, particularly among the Netherlands, Denmark, and the United Kingdom, where some patients rely on the standardized cannabis strains produced by Bedrocan.

How Dutch Cannabis Regulations Contributed to Bedrocan's Bankruptcy

Since 2003, Bedrocan had been supplying the Dutch Medical Cannabis Board (BMC), the government agency responsible for purchasing and distributing prescription cannabis to pharmacies. The Dutch government terminated its purchase contract in January 2026, citing regulations governing public procurement and state aid.

This decision, made ahead of a planned regulatory overhaul, was intended to allow other cannabis producers to supply pharmacies directly, thereby circumventing the state monopoly. But the problem lies in the timing.

According to Bedrocan, the necessary amendment to the Dutch Opium Act will not take effect until July 1, 2028, thereby depriving the company of its main customer and any legal avenue to other buyers.

Addressing Business of Cannabis, the company's representative, Femke Starrenburg, explained that negotiations regarding existing cannabis inventories had failed.

«Unfortunately, no agreement could be reached with the Dutch Ministry of Health regarding payment for and the transfer of the remaining batches of medical cannabis. Without such an agreement, the necessary funding could not be secured, making bankruptcy inevitable.»

The restrictions imposed on the company have also prevented it from capitalizing on the growing international demand for medical cannabis.

Thousands of patients face uncertainty regarding access to medical cannabis

This bankruptcy has immediate repercussions for approximately 7,000 Dutch patients who receive prescription cannabis to treat conditions such as multiple sclerosis, epilepsy, and chronic pain.

Bedrocan produced five standardized cannabis strains with consistent THC and CBD concentrations, which allowed patients to maintain their established treatment regimens. Although government stockpiles are expected to cover domestic demand through the summer of 2027, authorities must secure alternative supplies through a European tender process.

The situation is particularly concerning in the United Kingdom, where some children with severe, treatment-resistant epilepsy rely on Bedrolite, the full-spectrum, high-CBD cannabis oil produced by Bedrocan, but also in Denmark.

According to Business of Cannabis, existing shipments of Bedrolite are still in storage in the Netherlands, but their distribution requires government authorization as part of the bankruptcy proceedings. Matt Hughes, a representative of the Medcan Family Foundation, issued this warning:

«Above all, Bedrocan's bankruptcy poses an immediate risk to the lives of children and young people who rely on Bedrolite to control devastating, drug-resistant seizures.»

According to some sources, moving production to Denmark would take at least six months, which rules out any immediate replacement.

Bedrocan's Danish operations are also undergoing restructuring

While Bedrocan’s Canadian operations are not affected by the Dutch bankruptcy proceedings, its Danish subsidiary is facing its own financial difficulties. Bedrocan Danmark ApS began formal restructuring proceedings on October 1, according to Business of Cannabis, even though production is continuing.

The Danish operation is financially tied to the Dutch parent company, which complicates efforts to preserve production capacity. In addition, the bankruptcy in the Netherlands affects approximately 68 employees at the Veendam and Emmeloord sites.

Bedrocan's bankruptcy comes as the European medical cannabis market continues to grow, particularly in Germany, where the Imports have increased significantly.

Or how regulations can destabilize a well-established company, even as demand has never been higher.